The increased expression of genes for tumor cell epitope presentation to CTLs by mavorixafor was accompanied by similarly elevated tumor inflammatory gene signature (TIS) scores (Fig. 4A) and gene expression scores for IFNγ responses: CXCL9, CXCL10, HLA-DRA, IDO1, and STAT1 (ref. 31; Fig. 4B), which are indicative of enhanced immune cell activation. This evidence concerns the gene CXCL10 and neoplasm.